PTC Therapeutics secures Russian approval for Translarna to treat Duchenne muscular dystrophy

PTC Therapeutics, a leading US-based biotechnology company, has received marketing approval in Russia for its innovative drug, Translarna (ataluren), designed to treat patients with Duchenne ... Read More